



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs

*Agreement addresses future production needs of IFN α ,
key component of IFN Kinoid¹*

Paris and Boston, November 23, 2016 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs, for the manufacture of interferon alpha (IFN α). Today's collaboration follows the recent acquisition of the technology for the manufacture of IFN α by Neovacs from AMEGABIOTECH.

This license agreement will allow Neovacs to directly transfer AMEGABIOTECH's technology to the production site of 3P Biopharmaceuticals, which will ensure the manufacture of the IFN α cytokine. As the only Spanish manufacturer of biological products in the healthcare field, 3P Biopharmaceuticals has a successful track record working with top pharma and biotech companies throughout Europe and the United States.

Miguel Sieler, CEO of Neovacs, said, *“This partnership is in line with the recent license agreement signed with AMEGABIOTECH. The completion of these two steps allows us to secure the complete production chain for the manufacture of IFN α , one of the primary raw materials of our most advanced product, IFN α Kinoid. In addition, the agreement complements the partnership signed earlier this year with Stellar Biotechnologies, the supplier of the other main component of our vaccine IFN α Kinoid, Keyhole Limpet Hemocyanin (KLH). Within the framework of this partnership, Stellar Biotechnologies holds 30% of Neostell, the production subsidiary of Neovacs.”*

Elena Erroba, Business Development Director of 3P Biopharmaceuticals, affirmed: *“3P Biopharmaceuticals is very happy with this collaboration. It will allow 3P Biopharmaceuticals to contribute to a very innovative therapeutic approach, with our strong competence in the field of manufacturing high quality protein.”*

¹ IFN α Kinoid: Therapeutic vaccine from Neovacs technology, which is composed of the targeted cytokine IFN α , conjugated with a carrier protein, Keyhole Limpet Hemocyanin.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading European CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products in mammalian, microbial and yeast expression systems. With a highly qualified team of experts, 3P supports its clients offering manufacturing related drug development solutions from initial research, through preclinical and clinical trials to commercialization. 3P was created and promoted by a group of shareholders and institutions with large expertise in the biotechnology and pharmaceutical sector. Thanks to their financial effort and full confidence, 3P has been able to consolidate its activity into the international market and has become a reference for the biotech sector.

<http://www.3pbio.com/>

About Neovacs Technology

Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its biological effects. Several autoimmune and inflammatory diseases (Type 1 diabetes, systemic lupus erythematosus, psoriasis, etc.) are characterized by a disorder of cytokines that are found produced in excess (ex: IFN α). This overproduction will promote inflammation and dysregulation of the immune system.

About Neovacs

Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

Investor Relations / Financial Communications Germany – MC Services

Raimund Gabriel

+49-89-21-02-28-30

raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group

Lee Roth / Joseph Green

+1-646-536-7012 / 7013

lroth@theruthgroup.com / jgreen@theruthgroup.com